Visão geral da empresa
A clinical-stage biotechnology firm, Xilio Therapeutics, Inc. is dedicated to the discovery and development of tumor-activated immuno-oncology therapies, specifically focusing on checkpoint inhibitors. The company operates within the Healthcare sector and the Biotechnology industry, a classification that denotes its engagement in the research and development of biological agents to treat diseases, often involving high-risk, high-reward development pipelines. As of the latest data, the entity commands a market capitalization of $50.25M, generates annual revenue of $43.77M, and employs a workforce of 76 individuals. These financial dimensions indicate that the company functions as a small-cap entity with a relatively lean operational structure, typical of early-to-mid stage biotech firms that prioritize capital allocation toward clinical trials over extensive commercial overhead. The valuation suggests a modest market footprint, where the price-to-sales metric of 1.15 reflects a valuation slightly above its revenue base, a common characteristic for companies in the biotechnology space that are transitioning from discovery phases toward commercialization.
Saúde financeira
Xilio Therapeutics reported a trailing twelve-month revenue of $43.77M, yet it posted a net income loss of $-35,036,000 and an EBITDA of $-40,441,000 during the same period. The substantial disparity between the positive revenue figure and the significant net loss reveals a cost structure where operating expenses, likely driven by research and development activities, heavily outweigh earnings before taxes, interest, and amortization. Despite the accounting losses, the company maintains a free cash flow of $8.03M, which provides a critical buffer of financial flexibility to fund ongoing clinical operations without immediate reliance on external equity financing. The gross margin stands at 100.0%, indicating that the cost of goods sold is negligible relative to revenue, a standard feature for pharmaceutical products where manufacturing costs are low compared to R&D investments. However, the operating margin of -86.5% and profit margin of -80.1% highlight the intense expense environment inherent in the clinical-stage development phase. The balance sheet demonstrates a conservative stance with $137.53M in cash against only $6.95M in debt, resulting in a debt-to-equity ratio of 19.71 which, while high numerically, reflects a capital structure dominated by equity rather than interest-bearing liabilities. Liquidity is further evidenced by a current ratio of 2.58, suggesting the company holds sufficient current assets to cover short-term obligations more than twice over. Return on Equity is recorded at -132.5% and Return on Assets at -23.2%, metrics that indicate management is currently deploying capital in a manner that generates negative returns, a typical scenario for biotech firms investing heavily in pipeline assets before achieving commercial profitability.
Avaliação de valorização
The trailing P/E ratio is N/A due to the company's lack of positive net income, while the forward P/E is calculated at -14.98, implying that the market prices the stock based on anticipated future earnings that are currently expected to be negative or that earnings are not yet realized. The price-to-book ratio is 1.12, suggesting that the market values the company at a slight premium over its net asset book value, which may reflect intangible assets or potential value in the drug pipeline not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 1.15 and an EV/EBITDA of 1.99 provide context for valuation in the absence of traditional earnings multiples, showing that the market values the company at roughly its revenue base. The stock has traded between a 52-week high of $16.52 and a 52-week low of $6.47, indicating significant price volatility within a wide range. The beta value of -0.12 is anomalous, as it implies a negative correlation with the broader market, meaning the stock tends to move inversely to the market index during periods of volatility. This negative beta suggests a unique risk profile that does not align with standard market movements, potentially influenced by specific sector-wide biotech dynamics or investor sentiment shifts.
Growth & Income
Xilio Therapeutics has experienced a revenue growth of 693.9% year-over-year, whereas earnings growth is N/A due to the company's continued losses. The divergence between rapid revenue expansion and negative earnings indicates that top-line growth is occurring while operating expenses are still scaling to meet clinical and commercial demands. As a non-dividend payer, the company does not distribute cash to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This approach signifies that the company prioritizes reinvesting all available cash flow, including the $8.03M in free cash flow, back into research, development, and clinical trials to advance its immuno-oncology portfolio. The overall growth and income profile is characterized by aggressive top-line expansion without current profitability, relying on a strong cash position to sustain operations until the pipeline generates commercial returns. The absence of dividends combined with negative earnings growth metrics underscores the company's strategy of capitalizing on future value creation rather than providing current income to investors.